- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03754764
A Feasibility and Safety Study of CD38 CAR-T Cell Immunotherapy for Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T Adoptive Cellular Immunotherapy
December 5, 2018 updated by: Han weidong, Chinese PLA General Hospital
Phase I/II Study to Evaluate Treatment of Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T Adoptive Cellular Immunotherapy With CAR-T Cells Targeting CD38
CD19-directed CAR-T cell therapy has shown promising results for the treatment of relapsed or refractory B-cell malignancies; however, a subset of patients relapse due to the loss of CD19 in tumor cells.
CD38 CAR-T cells can recognize and kill the CD19 negative malignant cells through recognition of CD38.
This is a phase 1/2 study designed to determine the safety of the gene-edited specificity CD38 CAR-T cells and the feasibility of making enough to treat patients with relapsed B-cell acute lymphoblastic leukemia after CD19 CAR-T adoptive cellular immunotherapy.
Study Overview
Status
Unknown
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
- To evaluate the feasibility and safety of specificity CD38 CAR-T cells in patients with relapsed or refractory leukemia and lymphoma.
- To evaluate the duration of in vivo persistence of adoptively transferred T cells, and the phenotype of persisting T cells.
Real Time polymerase chain receptor (RT-PCR) and Flow cytometry(FCM) analysis of PB,BM and lymph node will be used to detect and quantify survival of CD38 CAR-T cells over time.
SECONDARY OBJECTIVES:
- For patients with detectable disease, measure anti-tumor response due to specificity CD38 CAR-T cell infusions.
- The CAR-T cells will be administered by i.v. injection over 20-30 minutes as a using Day 0: 1-5x10e6/kg total dose on day 0.
Study Type
Interventional
Enrollment (Anticipated)
80
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Hejin Jia
- Phone Number: 86-10-55499341
- Email: PLAGH@QQ.COM
Study Contact Backup
- Name: Zhitao Gao, Dr
- Phone Number: 86-010-66937917
- Email: zhitaogao@qq.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100083
- Recruiting
- Biotherapeutic Department and Hematology Department of Chinese PLA
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
12 years to 70 years (ADULT, OLDER_ADULT, CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female participant
- 12 Years to 70 Years (Child, Adult, Senior)
- Patient with relapsed CD38+ B-cell acute lymphoblastic leukemia after CD19 CAR-T adoptive cellular immunotherapy
- Estimated life expectancy ≥ 12 weeks (according to investigator's judgement)
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
- Adequate organ function
Exclusion Criteria:
- Prior malignancy, except carcinoma in situ of the skin or cervix treated with curative intent and with no evidence of active disease
- Diagnosis of Burkitt's leukemia/lymphoma according to WHO classification or chronic myelogenous leukemia lymphoid blast crisis
- Richter's syndrome
- Presence of Grade II-IV (Glucksberg) or B-D (IBMTR) acute or extensive chronic GVHD at the time of screening
- Subjects with any autoimmune disease or any immune deficiency disease or other disease in need of immunosuppressive therapy
- Severe active infection (uncomplicated urinary tract infections, bacterial pharyngitis is allowed), Prophylactic antibiotic, antiviral and antifungal treatment is permissible
- Active hepatitis B, active hepatitis C, or any human immunodeficiency virus (HIV) infection at the time of screening
- Patient has an investigational medicinal product within the last 30 days prior to screening
- Previous treatment with investigational gene or cell therapy medicine products
- Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not exclusionary
- Pregnant or nursing women
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with Severe/Adverse Events as a Measure of Safety and Tolerability
Time Frame: 24 weeks
|
24 weeks
|
|
Copies numbers of CAR in peripheral blood(PB), bone marrow(BM)and lymph nodes
Time Frame: 24 weeks
|
24 weeks
|
|
MTD of specificity CD38 CAR-T cells
Time Frame: 4 weeks
|
The highest dose of specificity CD38 CAR-T cells that is estimated to result in defined Dose Limiting Toxicity (DLT) with the exception of allowable 'expected' AEs associated with the intravenous infusion of specificity CD38 CAR-T cells.
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Six-month Objective response rate of complete remission and partial remission
Time Frame: 24 weeks
|
24 weeks
|
Six-month Overall survival
Time Frame: 24 weeks
|
24 weeks
|
Six-month Progression free survival
Time Frame: 24 weeks
|
24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
November 23, 2018
Primary Completion (ANTICIPATED)
November 23, 2022
Study Completion (ANTICIPATED)
November 23, 2022
Study Registration Dates
First Submitted
November 24, 2018
First Submitted That Met QC Criteria
November 24, 2018
First Posted (ACTUAL)
November 27, 2018
Study Record Updates
Last Update Posted (ACTUAL)
December 7, 2018
Last Update Submitted That Met QC Criteria
December 5, 2018
Last Verified
December 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHN-PLAGH-BT-038
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T ACI
-
Seoul National University HospitalRecruitingVery High Risk Acute Lymphoblastic Leukemia | CD19 CAR-T TherapyKorea, Republic of
-
Therapeutic Advances in Childhood Leukemia ConsortiumGlaxoSmithKline; NovartisTerminatedRelapsed T-Cell Acute Lymphoblastic Leukemia | Relapsed T-Cell Lymphoblastic LymphomaUnited States, France, Canada, Australia, Austria, Italy, Netherlands
-
Shanghai Longyao Biotechnology Inc., Ltd.UnknownThe Clinical Study of CD19 UCAR-T Cells in Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL)B-cell Acute Lymphoblastic Leukemia (B-ALL) | Safety and Efficacy of CD19 UCAR-T CellsChina
-
Mundipharma Research LimitedInnovative Therapies For Children with Cancer ConsortiumTerminatedRelapsed or Refractory T-cell Acute Lymphoblastic Leukaemia | B-cell Precursor Acute Lymphoblastic Leukaemia | T-cell Non-Hodgkin's LymphomaCzech Republic, Austria, France, Germany, Italy, United Kingdom
-
Shenzhen University General HospitalUnknownRefractory B Acute Lymphoblastic Leukemia | Relapse | B ALL | Dual-target CAR-T CellsChina
-
Shenzhen BinDeBio Ltd.Children's Hospital of Fudan UniversityActive, not recruitingRelapsed B-cell Acute Lymphoblastic Leukemia, Childhood | Refractory B-cell Acute Lymphoblastic Leukemia, Childhood | Relapsed/Refractory B-cell Lymphoma, ChildhoodChina
-
Shenzhen BinDeBio Ltd.Xiangya Hospital of Central South UniversityRecruitingRelapsed B-cell Acute Lymphoblastic Leukemia, Childhood | Refractory B-cell Acute Lymphoblastic Leukemia, Childhood | Relapsed/Refractory B-cell Lymphoma, ChildhoodChina
-
Shenzhen BinDeBio Ltd.The First Affiliated Hospital of Zhengzhou UniversityUnknownRefractory B-cell Acute Lymphoblastic Leukemia | Relapsed B-cell Acute Lymphoblastic Leukemia | Relapsed/Refractory B-cell LymphomaChina
-
University of WashingtonNational Cancer Institute (NCI)WithdrawnRecurrent Adult Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | Recurrent B Lymphoblastic Lymphoma | Refractory B Lymphoblastic Lymphoma | B Lymphoblastic Lymphoma | Recurrent T Lymphoblastic Leukemia/Lymphoma | Refractory T Lymphoblastic Lymphoma | T Acute Lymphoblastic Leukemia | T...United States
-
First Affiliated Hospital of Harbin Medical UniversityUnknownCD19-chimeric Antigen Receptor T Cells | Relapsed and/or Refractory Acute Lymphoblastic Leukemia | the Haploidentical Hematopoietic Stem Cell TransplantationChina
Clinical Trials on Specificity CD38 CAR-T Cells
-
Chinese PLA General HospitalUnknown
-
Zhejiang UniversityYake Biotechnology Ltd.Recruiting
-
Sorrento Therapeutics, Inc.CompletedRelapsed or Refractory Multiple MyelomaUnited States
-
PersonGen BioTherapeutics (Suzhou) Co., Ltd.Anhui Provincial Hospital; The First People's Hospital of Hefei; Hefei Binhu...UnknownFollicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | Diffuse Large Cell Lymphoma | B-cell Prolymphocytic LeukemiaChina
-
PersonGen BioTherapeutics (Suzhou) Co., Ltd.Anhui Provincial HospitalUnknownFollicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | Diffuse Large Cell Lymphoma | B-cell Prolymphocytic LeukemiaChina
-
Chinese PLA General HospitalUnknownB Cell Lymphoma | B Cell LeukemiaChina
-
Chinese PLA General HospitalUnknownRelapsed Adult Myeloid Leukemia | Chemotherapy Refractory Adult Myeloid LeukemiaChina
-
Shenzhen Geno-Immune Medical InstituteThe Second Affiliated Hospital of Hainan Medical University; Beijing Jingdu...Recruiting
-
Second Affiliated Hospital of Xi'an Jiaotong UniversityNanjing Legend Biotech Co.Terminated
-
Second Affiliated Hospital of Xi'an Jiaotong UniversityNanjing Legend Biotech Co.WithdrawnRefractory B Acute Lymphoblastic Leukemia | Relapse B Acute Lymphoblastic LeukemiaChina